Skillz Inc. (SKLZ): Nasdaq/NYSE listing notice — Skillz receives NYSE non-compliance notice; stock price below $1.00 average

Skillz Inc.

NYSE notified Skillz on Dec 16, 2022 that its Class A common stock average closing price was below $1.00 over 30 consecutive trading days.
No immediate delisting; stock continues trading on NYSE while Skillz pursues cure.
Company must notify NYSE by Jan 3, 2023 of intent to cure; has up to six months to regain compliance.
Cure options include a reverse stock split, subject to stockholder approval at next annual meeting.
If stock price exceeds $1.00 and stays above for 30 trading days after approval, deficiency deemed cured.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Skillz Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

Exchange: nyse
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 802.01C

Exact text from the filing

December 16, 2022, Skillz Inc. (“Skillz” or the “Company”) was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A common stock was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of Skillz’s Class A common stock from the NYSE. The Company plans to notify the NYSE by January 3, 2023 that it intends to cure the stock price deficiency and to return to compliance with the NYSE continued listi

View on SEC.gov

Browse all listing & compliance notices →

Skillz Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-032338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.